Symbols / ARDX Stock $6.61 -2.51% Ardelyx, Inc.
ARDX (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | reit | Wedbush | Outperform → Outperform | $19 |
| 2026-02-20 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2026-02-20 | reit | BTIG | Buy → Buy | $17 |
| 2026-01-29 | reit | BTIG | Buy → Buy | $17 |
| 2026-01-21 | main | Wedbush | Outperform → Outperform | $19 |
| 2026-01-09 | main | Citigroup | Buy → Buy | $14 |
| 2026-01-09 | up | Piper Sandler | Neutral → Overweight | $16 |
| 2026-01-09 | main | BTIG | Buy → Buy | $17 |
| 2025-11-04 | main | Piper Sandler | Neutral → Neutral | $10 |
| 2025-11-03 | main | Citigroup | Buy → Buy | $11 |
| 2025-10-31 | main | TD Cowen | Buy → Buy | $10 |
| 2025-08-06 | main | Piper Sandler | Neutral → Neutral | $9 |
| 2025-08-05 | main | Wedbush | Outperform → Outperform | $14 |
| 2025-08-05 | main | Raymond James | Outperform → Outperform | $12 |
| 2025-05-02 | main | Citigroup | Buy → Buy | $10 |
| 2025-03-07 | init | Scotiabank | — → Sector Outperform | $15 |
| 2025-02-21 | reit | Raymond James | Strong Buy → Strong Buy | $13 |
| 2025-02-21 | reit | HC Wainwright & Co. | Neutral → Neutral | $6 |
| 2025-01-27 | main | Piper Sandler | Neutral → Neutral | $8 |
| 2025-01-16 | reit | HC Wainwright & Co. | Neutral → Neutral | $6 |
- Ardelyx: Low Price, But High Implied Valuation (NASDAQ:ARDX) - Seeking Alpha Fri, 08 May 2026 14
- Assessing Ardelyx (ARDX) Valuation After New Long Term XPHOZAH Safety Data Presentation - simplywall.st Mon, 11 May 2026 19
- Dialysis drug cut phosphate without shifting other electrolytes in trials - Stock Titan hu, 07 May 2026 12
- Is Ardelyx (ARDX) Offering Long-Term Value After Recent Share Price Swings? - Yahoo Finance Sat, 04 Apr 2026 07
- Insider Purchase: Director at $ARDX Buys 333,333 Shares - Quiver Quantitative ue, 24 Feb 2026 08
- ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits Fri, 20 Feb 2026 12
- TradingKey - TradingKey ue, 12 May 2026 07
- Kidney meeting picks Ardelyx study on phosphorus drug XPHOZAH - Stock Titan Mon, 27 Apr 2026 07
- $ARDX stock is up 9% today. Here's what we see in our data. - Quiver Quantitative Fri, 01 May 2026 07
- Is Ardelyx (ARDX) Offering Value After Recent Share Price Swings And DCF Estimate Gap - Yahoo Finance Sat, 25 Apr 2026 07
- $ARDX stock is down 14% today. Here's what we see in our data. - Quiver Quantitative Fri, 20 Feb 2026 08
- Why Ardelyx (ARDX) Is Up 10.3% After New Long-Term XPHOZAH Dialysis Data And What's Next - simplywall.st Sat, 09 May 2026 09
- Ardelyx says IBSRELA sales hit $70.1M as it funds new trials - Stock Titan hu, 30 Apr 2026 07
- Assessing Ardelyx (ARDX) Valuation After Recent Share Price Weakness - Yahoo Finance ue, 10 Mar 2026 07
- ARDELYX ($ARDX) Releases Q1 2026 Earnings - Quiver Quantitative hu, 30 Apr 2026 20
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
407.32
+22.09%
|
333.62
+168.06%
|
124.46
+138.61%
|
52.16
|
| Operating Revenue |
|
407.32
+22.09%
|
333.62
+168.06%
|
124.46
+138.61%
|
52.16
|
| Cost Of Revenue |
|
39.54
-21.80%
|
50.56
+184.10%
|
17.80
+332.23%
|
4.12
|
| Reconciled Cost Of Revenue |
|
39.54
-21.80%
|
50.56
+184.10%
|
17.80
+332.23%
|
4.12
|
| Gross Profit |
|
367.78
+29.93%
|
283.06
+165.38%
|
106.66
+122.02%
|
48.04
|
| Operating Expense |
|
408.76
+31.43%
|
311.01
+83.01%
|
169.94
+52.00%
|
111.80
|
| Research And Development |
|
71.53
+36.72%
|
52.32
+47.22%
|
35.54
+0.95%
|
35.20
|
| Selling General And Administration |
|
337.23
+30.36%
|
258.69
+92.48%
|
134.40
+75.46%
|
76.60
|
| General And Administrative Expense |
|
—
|
—
|
—
|
76.60
|
| Other Gand A |
|
—
|
—
|
—
|
76.60
|
| Total Expenses |
|
448.30
+23.99%
|
361.56
+92.60%
|
187.73
+61.95%
|
115.92
|
| Operating Income |
|
-40.98
-46.61%
|
-27.95
+55.83%
|
-63.28
+0.76%
|
-63.76
|
| Total Operating Income As Reported |
|
-40.98
-46.61%
|
-27.95
+55.83%
|
-63.28
+0.76%
|
-63.76
|
| EBITDA |
|
-29.17
-74.55%
|
-16.71
+69.81%
|
-55.35
+9.23%
|
-60.98
|
| Normalized EBITDA |
|
-29.17
-74.55%
|
-16.71
+69.81%
|
-55.35
+9.23%
|
-60.98
|
| Reconciled Depreciation |
|
3.06
+48.28%
|
2.06
+59.67%
|
1.29
+12.94%
|
1.14
|
| EBIT |
|
-32.23
-71.67%
|
-18.78
+66.85%
|
-56.65
+8.82%
|
-62.13
|
| Net Income |
|
-61.60
-57.40%
|
-39.14
+40.76%
|
-66.07
+1.70%
|
-67.21
|
| Pretax Income |
|
-60.63
-55.98%
|
-38.87
+40.67%
|
-65.52
+2.50%
|
-67.20
|
| Net Non Operating Interest Income Expense |
|
-28.40
-41.33%
|
-20.09
-126.44%
|
-8.87
-74.93%
|
-5.07
|
| Interest Expense Non Operating |
|
28.40
+41.33%
|
20.09
+126.44%
|
8.87
+74.93%
|
5.07
|
| Net Interest Income |
|
-28.40
-41.33%
|
-20.09
-126.44%
|
-8.87
-74.93%
|
-5.07
|
| Interest Expense |
|
28.40
+41.33%
|
20.09
+126.44%
|
8.87
+74.93%
|
5.07
|
| Other Income Expense |
|
8.74
-4.68%
|
9.17
+38.37%
|
6.63
+306.00%
|
1.63
|
| Other Non Operating Income Expenses |
|
8.74
-4.68%
|
9.17
+38.37%
|
6.63
+306.00%
|
1.63
|
| Tax Provision |
|
0.97
+264.29%
|
0.27
-51.37%
|
0.55
+6737.50%
|
0.01
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-61.60
-57.40%
|
-39.14
+40.76%
|
-66.07
+1.70%
|
-67.21
|
| Net Income From Continuing Operation Net Minority Interest |
|
-61.60
-57.40%
|
-39.14
+40.76%
|
-66.07
+1.70%
|
-67.21
|
| Net Income From Continuing And Discontinued Operation |
|
-61.60
-57.40%
|
-39.14
+40.76%
|
-66.07
+1.70%
|
-67.21
|
| Net Income Continuous Operations |
|
-61.60
-57.40%
|
-39.14
+40.76%
|
-66.07
+1.70%
|
-67.21
|
| Normalized Income |
|
-61.60
-57.40%
|
-39.14
+40.76%
|
-66.07
+1.70%
|
-67.21
|
| Net Income Common Stockholders |
|
-61.60
-57.40%
|
-39.14
+40.76%
|
-66.07
+1.70%
|
-67.21
|
| Diluted EPS |
|
-0.26
-52.94%
|
-0.17
+43.33%
|
-0.30
+28.57%
|
-0.42
|
| Basic EPS |
|
-0.26
-52.94%
|
-0.17
+43.33%
|
-0.30
+28.57%
|
-0.42
|
| Basic Average Shares |
|
241.03
+2.47%
|
235.23
+7.25%
|
219.33
+38.21%
|
158.69
|
| Diluted Average Shares |
|
241.03
+2.47%
|
235.23
+7.25%
|
219.33
+38.21%
|
158.69
|
| Diluted NI Availto Com Stockholders |
|
-61.60
-57.40%
|
-39.14
+40.76%
|
-66.07
+1.70%
|
-67.21
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
297.58
|
| Current Assets |
|
246.11
|
| Cash Cash Equivalents And Short Term Investments |
|
184.30
|
| Cash And Cash Equivalents |
|
21.47
|
| Cash Equivalents |
|
18.64
|
| Cash Financial |
|
2.83
|
| Other Short Term Investments |
|
162.83
|
| Receivables |
|
22.03
|
| Accounts Receivable |
|
22.03
|
| Inventory |
|
12.45
|
| Prepaid Assets |
|
18.93
|
| Other Current Assets |
|
8.41
|
| Total Non Current Assets |
|
51.47
|
| Net PPE |
|
6.60
|
| Gross PPE |
|
16.80
|
| Accumulated Depreciation |
|
-10.20
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
2.43
|
| Other Properties |
|
5.63
|
| Leases |
|
8.73
|
| Investments And Advances |
|
—
|
| Non Current Prepaid Assets |
|
4.24
|
| Other Non Current Assets |
|
40.63
|
| Total Liabilities Net Minority Interest |
|
130.76
|
| Current Liabilities |
|
50.39
|
| Payables And Accrued Expenses |
|
21.30
|
| Payables |
|
11.14
|
| Accounts Payable |
|
11.14
|
| Current Accrued Expenses |
|
10.16
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
12.60
|
| Current Debt And Capital Lease Obligation |
|
4.43
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
4.43
|
| Current Deferred Liabilities |
|
7.18
|
| Current Deferred Revenue |
|
7.18
|
| Other Current Liabilities |
|
4.88
|
| Total Non Current Liabilities Net Minority Interest |
|
80.37
|
| Long Term Debt And Capital Lease Obligation |
|
51.55
|
| Long Term Debt |
|
49.82
|
| Long Term Capital Lease Obligation |
|
1.73
|
| Non Current Deferred Liabilities |
|
28.82
|
| Non Current Deferred Revenue |
|
8.64
|
| Stockholders Equity |
|
166.82
|
| Common Stock Equity |
|
166.82
|
| Capital Stock |
|
0.02
|
| Common Stock |
|
0.02
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
232.45
|
| Ordinary Shares Number |
|
232.45
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
1,012.77
|
| Retained Earnings |
|
-846.20
|
| Gains Losses Not Affecting Retained Earnings |
|
0.22
|
| Other Equity Adjustments |
|
0.22
|
| Total Equity Gross Minority Interest |
|
166.82
|
| Total Capitalization |
|
216.64
|
| Working Capital |
|
195.72
|
| Invested Capital |
|
216.64
|
| Total Debt |
|
55.98
|
| Net Debt |
|
28.35
|
| Capital Lease Obligations |
|
6.16
|
| Net Tangible Assets |
|
166.82
|
| Tangible Book Value |
|
166.82
|
| Interest Payable |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-42.48
+5.19%
|
-44.81
+50.06%
|
-89.72
-28.09%
|
-70.04
|
| Cash Flow From Continuing Operating Activities |
|
-42.48
+5.19%
|
-44.81
+50.06%
|
-89.72
-28.09%
|
-70.04
|
| Net Income From Continuing Operations |
|
-61.60
-57.40%
|
-39.14
+40.76%
|
-66.07
+1.70%
|
-67.21
|
| Depreciation Amortization Depletion |
|
3.06
+48.28%
|
2.06
+59.67%
|
1.29
+12.94%
|
1.14
|
| Depreciation |
|
—
|
—
|
—
|
—
|
| Depreciation And Amortization |
|
3.06
+48.28%
|
2.06
+59.67%
|
1.29
+12.94%
|
1.14
|
| Other Non Cash Items |
|
-1.55
-138.33%
|
4.05
-17.54%
|
4.91
-19.50%
|
6.10
|
| Stock Based Compensation |
|
48.96
+30.98%
|
37.38
+176.28%
|
13.53
+25.86%
|
10.75
|
| Operating Gains Losses |
|
—
|
—
|
—
|
-1.26
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
0.58
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
|
0.00
+100.00%
|
-1.26
|
| Change In Working Capital |
|
-31.35
+36.24%
|
-49.17
-13.33%
|
-43.39
-121.64%
|
-19.57
|
| Change In Receivables |
|
-14.14
+60.35%
|
-35.67
-149.50%
|
-14.30
-97.73%
|
-7.23
|
| Changes In Account Receivables |
|
-14.14
+60.35%
|
-35.67
-149.50%
|
-14.30
-97.73%
|
-7.23
|
| Change In Inventory |
|
-31.92
+23.44%
|
-41.70
-97.23%
|
-21.14
+25.42%
|
-28.35
|
| Change In Prepaid Assets |
|
-2.39
-206.92%
|
2.24
+114.33%
|
-15.63
-739.31%
|
-1.86
|
| Change In Payables And Accrued Expense |
|
21.95
-22.88%
|
28.46
+215.54%
|
9.02
-29.79%
|
12.85
|
| Change In Accrued Expense |
|
18.71
-20.70%
|
23.60
+169.99%
|
8.74
+39.53%
|
6.26
|
| Change In Payable |
|
3.23
-33.46%
|
4.86
+1642.65%
|
0.28
-95.76%
|
6.58
|
| Change In Account Payable |
|
3.23
-33.46%
|
4.86
+1642.65%
|
0.28
-95.76%
|
6.58
|
| Change In Other Working Capital |
|
-3.01
-244.02%
|
2.09
-19.23%
|
2.59
-69.56%
|
8.51
|
| Change In Other Current Liabilities |
|
-1.83
+60.18%
|
-4.59
-16.80%
|
-3.93
-12.52%
|
-3.49
|
| Investing Cash Flow |
|
-8.96
+51.09%
|
-18.32
+86.04%
|
-131.25
-812.72%
|
18.41
|
| Cash Flow From Continuing Investing Activities |
|
-8.96
+51.09%
|
-18.32
+86.04%
|
-131.25
-812.72%
|
18.41
|
| Net PPE Purchase And Sale |
|
-1.49
-47.58%
|
-1.01
-193.90%
|
-0.34
-119.74%
|
1.74
|
| Purchase Of PPE |
|
-1.49
-47.58%
|
-1.01
-193.90%
|
-0.34
-525.45%
|
-0.06
|
| Sale Of PPE |
|
—
|
0.00
|
0.00
-100.00%
|
1.80
|
| Capital Expenditure |
|
-1.49
-47.58%
|
-1.01
-193.90%
|
-0.34
-525.45%
|
-0.06
|
| Net Investment Purchase And Sale |
|
-7.47
+56.86%
|
-17.31
+86.78%
|
-130.90
-885.17%
|
16.67
|
| Purchase Of Investment |
|
-218.92
-12.18%
|
-195.16
+9.32%
|
-215.22
-327.64%
|
-50.33
|
| Sale Of Investment |
|
211.46
+18.89%
|
177.85
+110.92%
|
84.32
+25.85%
|
67.00
|
| Financing Cash Flow |
|
54.51
-48.86%
|
106.59
-27.14%
|
146.29
+94.18%
|
75.34
|
| Cash Flow From Continuing Financing Activities |
|
54.51
-48.86%
|
106.59
-27.14%
|
146.29
+94.18%
|
75.34
|
| Net Issuance Payments Of Debt |
|
48.67
-51.06%
|
99.45
+344.26%
|
22.39
+468.98%
|
-6.07
|
| Issuance Of Debt |
|
48.67
-51.06%
|
99.45
+344.26%
|
22.39
-17.00%
|
26.97
|
| Repayment Of Debt |
|
—
|
0.00
|
0.00
+100.00%
|
-33.04
|
| Long Term Debt Issuance |
|
48.67
-51.06%
|
99.45
+344.26%
|
22.39
-17.00%
|
26.97
|
| Long Term Debt Payments |
|
—
|
0.00
|
0.00
+100.00%
|
-33.04
|
| Net Long Term Debt Issuance |
|
48.67
-51.06%
|
99.45
+344.26%
|
22.39
+468.98%
|
-6.07
|
| Net Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
119.24
+66.47%
|
71.62
|
| Proceeds From Stock Option Exercised |
|
5.84
-28.23%
|
8.14
+593.78%
|
1.17
+480.69%
|
0.20
|
| Net Other Financing Charges |
|
—
|
-1.00
-128.57%
|
3.50
-63.47%
|
9.58
|
| Changes In Cash |
|
3.07
-92.94%
|
43.46
+158.21%
|
-74.67
-414.90%
|
23.71
|
| Beginning Cash Position |
|
64.93
+202.43%
|
21.47
-77.67%
|
96.14
+32.74%
|
72.43
|
| End Cash Position |
|
68.00
+4.72%
|
64.93
+202.43%
|
21.47
-77.67%
|
96.14
|
| Free Cash Flow |
|
-43.98
+4.03%
|
-45.82
+49.12%
|
-90.06
-28.48%
|
-70.10
|
| Interest Paid Supplemental Data |
|
15.72
+37.77%
|
11.41
+169.06%
|
4.24
+46.16%
|
2.90
|
| Income Tax Paid Supplemental Data |
|
0.48
+82.33%
|
0.27
+421.57%
|
0.05
+750.00%
|
0.01
|
| Amortization Of Securities |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
119.24
+66.47%
|
71.62
|
| Issuance Of Capital Stock |
|
0.00
|
0.00
-100.00%
|
119.24
+66.47%
|
71.62
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-04-30 View
- 8-K2026-04-30 View
- 42026-04-17 View
- 42026-03-18 View
- 42026-02-25 View
- 42026-02-23 View
- 42026-02-23 View
- 42026-02-23 View
- 42026-02-23 View
- 42026-02-23 View
- 42026-02-23 View
- 42026-02-23 View
- 42026-02-23 View
- 42026-02-23 View
- 10-K2026-02-19 View
- 8-K2026-02-19 View
- 42026-01-27 View
- 42026-01-26 View
- 42026-01-26 View
- 42026-01-26 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|